{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+Auto+Injector",
    "query": {
      "intervention": "Intramuscular Auto Injector"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T04:25:03.910Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02940522",
      "title": "Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women"
      ],
      "interventions": [
        {
          "name": "Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 75 Years · Female only"
      },
      "enrollment_count": 122,
      "start_date": "2016-09",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 5,
      "location_summary": "Anaheim, California • DeLand, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02940522"
    },
    {
      "nct_id": "NCT02937766",
      "title": "Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women"
      ],
      "interventions": [
        {
          "name": "Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 75 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2016-10-07",
      "completion_date": "2017-03-27",
      "has_results": true,
      "last_update_posted_date": "2022-04-21",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02937766"
    },
    {
      "nct_id": "NCT04207840",
      "title": "Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Epinephrine",
        "Albuterol",
        "Asthma",
        "Anaphylaxis"
      ],
      "interventions": [
        {
          "name": "Epinephrine (0.125 mg/inhalation)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Epinephrine Injection Auto-Injector (0.3mg/0.3mL)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Albuterol Sulfate (0.09 mg/inhalation)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Amphastar Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 28,
      "start_date": "2019-12-09",
      "completion_date": "2019-12-23",
      "has_results": true,
      "last_update_posted_date": "2021-03-30",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04207840"
    },
    {
      "nct_id": "NCT04679623",
      "title": "Study of Midazolam in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Status Epilepticus"
      ],
      "interventions": [
        {
          "name": "Midazolam",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Seizalam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Rafa Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2021-06-09",
      "completion_date": "2021-09-17",
      "has_results": false,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04679623"
    },
    {
      "nct_id": "NCT00319501",
      "title": "Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seizures",
        "Epilepsies, Partial",
        "Epilepsy, Complex Partial",
        "Epilepsy, Generalized",
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vanquix Auto-Injector (Diazepam Injection)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2006-01",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 86,
      "location_summary": "Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00319501"
    },
    {
      "nct_id": "NCT07210320",
      "title": "PK/PD Study of IN-001 Sublingual Spray in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Food Allergy",
        "Anaphylaxis",
        "Food Hypersensitivity",
        "Food Allergy Peanut"
      ],
      "interventions": [
        {
          "name": "Epinephrine Auto-Injector 0.3 mg/0.3 mL",
          "type": "DRUG"
        },
        {
          "name": "Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle",
          "type": "DRUG"
        },
        {
          "name": "IN-001 9.06 mg Sublingual Spray",
          "type": "DRUG"
        },
        {
          "name": "IN-001 13.59 mg Sublingual Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insignis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 32,
      "start_date": "2025-10-24",
      "completion_date": "2026-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07210320"
    },
    {
      "nct_id": "NCT01887418",
      "title": "Pharmacokinetic Study of Testosterone Enanthate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "QuickShot™ - 50 mg Treatment B",
          "type": "DRUG"
        },
        {
          "name": "QuickShot™ - 100 mg Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Delatestryl 200 mg IM Treatment C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Antares Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "18 Years to 75 Years · Male only"
      },
      "enrollment_count": 39,
      "start_date": "2013-09",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2018-01-11",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 1,
      "location_summary": "Brookline, Massachusetts",
      "locations": [
        {
          "city": "Brookline",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01887418"
    },
    {
      "nct_id": "NCT03386591",
      "title": "Comparison of Naloxone Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "Naloxone",
          "type": "DRUG"
        },
        {
          "name": "Mucosal atomization device and syringe",
          "type": "DEVICE"
        },
        {
          "name": "Narcan",
          "type": "DEVICE"
        },
        {
          "name": "Intramuscular Auto Injector",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-01-03",
      "completion_date": "2018-03-06",
      "has_results": false,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-09-09T04:25:03.910Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386591"
    }
  ]
}